In summary, this review tries to address the following question: In patients with HS, does treatment with TNF-alpha inhibitors (e.g., adalimumab) produce significant changes in systemic inflammatory markers (e.g., CRP, ESR)? The gene discussed is CRP; the disease is histiocytic sarcoma.